(Albany, US) DelveInsight has launched a new report on "Hepatic Encephalopathy - Market Insights, Epidemiology, and Market Forecast-2030"
DelveInsight's "Hepatic Encephalopathy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the report:
- Hepatic Encephalopathy is a prevalent complication of liver disease and occurs in approximately 30–45% of patients with cirrhosis and 10–50% of patients with a transjugular intrahepatic portosystemic shunt.
- Overt Hepatic Encephalopathy (HE) will occur in 30%-40% of those with cirrhosis at some time during their clinical course and the survivors in most cases repeatedly. Minimal HE (MHE) or covert HE (CHE) occurs in 20%-80% of patients with cirrhosis.
Request for free sample report: https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market
Scope of the Report
- The report covers the descriptive overview of Hepatic Encephalopathy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Hepatic Encephalopathy epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Hepatic Encephalopathy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Hepatic Encephalopathy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hepatic Encephalopathy market
Hepatic Encephalopathy (HE), sometimes referred to as portosystemic encephalopathy or PSE, is a condition that causes temporary worsening of brain function in people with advanced liver disease. It occurs in individuals with liver disease when toxins that are normally cleared in the liver accumulate in the blood eventually traveling to and damaging the brain. The condition can decrease mental function and cause stupor and even coma.
HE is clinically classified into three major categories, according to the underlying hepatic condition:
- Type A: Encephalopathy from acute liver failure
- Type B: Encephalopathy caused by portosystemic shunting, without intrinsic liver disease
- Type C: Encephalopathy of cirrhosis associated with portosystemic shunting
A number of scales have been designed for the diagnosis of HE, among which West-Haven Criteria is most commonly used:
Grade 0: Minimal HE, Grade 1: Mild HE [Covert HE stages], Grade 2: Moderate HE, Grade 3: Severe HE, Grade 5: Coma [Overt HE stages]
Request for free sample report: https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market
Drugs covered
- SYNB-1020
- MNK6106
- And many others
The key players in Hepatic Encephalopathy market are:
- Synlogic
- Mallinckrodt
- Aska Pharmaceuticals
- Wockhardt
- And many others
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Hepatic Encephalopathy market
- To understand the future market competition in the Hepatic Encephalopathy market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Hepatic Encephalopathy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Hepatic Encephalopathy market
- To understand the future market competition in the Hepatic Encephalopathy market
Request for free sample report: https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market
Table of contents:
1. Key Insights
2. Executive Summary of Hepatic Encephalopathy
3. Competitive Intelligence Analysis for Hepatic Encephalopathy
4. Hepatic Encephalopathy: Market Overview at a Glance
4.1. Hepatic Encephalopathy Total Market Share (%) Distribution in 2017
4.2. Hepatic Encephalopathy Total Market Share (%) Distribution in 2030
5. Hepatic Encephalopathy: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Hepatic Encephalopathy Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Hepatic Encephalopathy Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Hepatic Encephalopathy Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Hepatic Encephalopathy Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Hepatic Encephalopathy Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Hepatic Encephalopathy Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Hepatic Encephalopathy Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Hepatic Encephalopathy Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Hepatic Encephalopathy Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Hepatic Encephalopathy Treatment and Management
8.2. Hepatic Encephalopathy Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Hepatic Encephalopathy Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Hepatic Encephalopathy: Seven Major Market Analysis
13.1. Key Findings
13.2. Hepatic Encephalopathy Market Size in 7MM
13.3. Hepatic Encephalopathy Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Hepatic Encephalopathy Total Market Size in the United States
15.1.2. Hepatic Encephalopathy Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Hepatic Encephalopathy Total Market Size in Germany
15.3.2. Hepatic Encephalopathy Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Hepatic Encephalopathy Total Market Size in France
15.4.2. Hepatic Encephalopathy Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Hepatic Encephalopathy Total Market Size in Italy
15.5.2. Hepatic Encephalopathy Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Hepatic Encephalopathy Total Market Size in Spain
15.6.2. Hepatic Encephalopathy Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Hepatic Encephalopathy Total Market Size in the United Kingdom
15.7.2. Hepatic Encephalopathy Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Hepatic Encephalopathy Total Market Size in Japan
15.8.3. Hepatic Encephalopathy Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Hepatic Encephalopathy
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/hepatic-encephalopathy-market
